Log in

Relevant bibliographies by topics / Anti asthma drug

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Anti asthma drug'

Author: Grafiati

Published: 4 June 2021

Last updated: 10 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Anti asthma drug.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Anti asthma drug"

1

Rottier, Bart L., and Eric J. Duiverman. "Anti-inflammatory drug therapy in asthma." Paediatric Respiratory Reviews 10, no. 4 (December 2009): 214–19. http://dx.doi.org/10.1016/j.prrv.2009.06.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Snell, N. J. C. "Drug interactions with anti-asthma medication." Respiratory Medicine 88, no. 2 (February 1994): 83–88. http://dx.doi.org/10.1016/0954-6111(94)90019-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Meszaros, A., V. Zoltan, and E. Galik. "PRS14: ASTHMA AND ANTI-ASTHMA DRUG USE IN HUNGARY." Value in Health 3, no. 5 (September 2000): 331–32. http://dx.doi.org/10.1016/s1098-3015(11)70710-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Calhoun, W. "Anti-leukotrienes for asthma." Current Opinion in Pharmacology 1, no. 3 (June 1, 2001): 230–34. http://dx.doi.org/10.1016/s1471-4892(01)00041-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Knyazheskaya, N. P., A. S. Belevskiy, and E. V. Safoshkina. "Anti-IgE therapy for severe atopic asthma." Russian Journal of Allergy 16, no. 1 (February 15, 2019): 71–78. http://dx.doi.org/10.36691/rja30.

Full text

Abstract:

The first targeted drug that is used for patients with uncontrolled moderate and severe atopic asthma (BA) was anti-IgE drug omalizumab (Xolar®). This drug is prescribed to patients with moderate to severe atopic BA, which is not controlled by baseline therapy corresponding to stage 4 (level of evidence A). Clinical studies have convincingly demonstrated that in patients with severe asthma requiring treatment with high doses of inhaled corticosteroids or oral glucocorticosteroids, treatment with Xolar® reduces the frequency of exacerbations of BA, reduces the severity of asthma and allows for steroid-dependent BA to cancel or significantly reduce the dose of systemic corticosteroids. In addition, the anti-inflammatory effect of the drug has been proven. Studies in recent years provide more and more data on the positive impact of omalizumab on the remodeling of the respiratory tract.

APA, Harvard, Vancouver, ISO, and other styles

6

Vakily, Majid, Reza Mehvar, and Dion Brocks. "Stereoselective Pharmacokinetics and Pharmacodynamics of Anti-Asthma Agents." Annals of Pharmacotherapy 36, no. 4 (April 2002): 693–701. http://dx.doi.org/10.1345/aph.1a248.

Full text

Abstract:

OBJECTIVE: To review the previously published studies on pharmacokinetics and pharmacodynamics of chiral drugs used in the treatment of asthma. DATA SOURCES: Primary and review articles were identified with a MEDLINE search (1980–May 2001) and through secondary sources. STUDY SELECTION AND DATA EXTRACTION: All English-language studies and reviews obtained from the MEDLINE search pertaining to stereoselective pharmacokinetics and pharmacodynamics of chiral anti-asthma drugs were assessed. DATA SYNTHESIS: Several anti-asthma drugs (e.g., β2-adrenergic agonists, leukotriene modifiers) are chiral and marketed as racemates, which consist of equal proportions of 2 enantiomers. Significant stereoselectivity has also been reported in pharmacodynamics and pharmacokinetics of the β2-agonists. The enantiomers of β2-agonists in the R configuration are primarily responsible for the bronchodilating effects of the racemate. The plasma concentrations of the enantiomers of anti-asthma drugs may differ as a reflection of stereoselectivity in clearance, volume of distribution, and route of administration. CONCLUSIONS: Stereoselectivity in the pharmacokinetics of anti-asthma drugs may complicate the relationship between dose and/or plasma concentration of racemic drug versus effect relationship. An appreciation of the stereoselective pharmacokinetics and pharmacodynamics of chiral anti-asthma drugs may optimize the use of these agents in asthmatic patients.

APA, Harvard, Vancouver, ISO, and other styles

7

Trivedi, Nitant, Hemangini R. Acharya, Manish J. Barvaliya, and C. B. Tripathi. "Prescribing pattern in patients of asthma visiting outpatient departments of a tertiary care hospital: a cross-sectional, observational study." International Journal of Basic & Clinical Pharmacology 6, no. 3 (February 24, 2017): 587. http://dx.doi.org/10.18203/2319-2003.ijbcp20170818.

Full text

Abstract:

Background: Objective of the study was to evaluate the prescribing pattern in patients of asthma visiting outpatient departments.Methods: Collected prescriptions were analyzed for demographic variables, proportions of various comorbid conditions, average number of drugs per prescription, average number of anti-asthmatic drugs per prescription, proportion of prescription with antibiotics, fixed dose combinations, and generic/brand names, proportion of formulations utilized, proportion of concomitant medications and possible drug interactions, average cost per prescription, average cost of antiasthmatic drugs per prescription, proportion of irrational prescription and adverse drug reactions.Results: Total 139 prescriptions were evaluated. Deriphyllin was the most commonly prescribed anti-asthmatic drug followed by beta agonist- steroid combination. Majority drugs were prescribed by inhalational route. Deriphyllin, and dexamethasone were prescribed by oral route and salbutamol was by both oral and inhalational route of administration. Antibiotics were prescribed to 24 patients. Possible drug interaction with deriphyllin was found in 15 prescriptions. Average cost per prescription was Rs. 193.4 (95%CI: 171.6-215.3).Conclusions: Prescribing pattern of asthma in our hospital shows more use of anti-asthmatic drugs. Standard treatment guideline should be followed. Role of methylxanthine in long term management of asthma should be justified.

APA, Harvard, Vancouver, ISO, and other styles

8

S., Narendra Babu, Vinoth Kumar C., and Nandini R. "Comparative study of adverse drug reaction pattern of two anti-asthma groups of drugs in a tertiary care hospital." International Journal of Basic & Clinical Pharmacology 8, no. 4 (March 23, 2019): 788. http://dx.doi.org/10.18203/2319-2003.ijbcp20191118.

Full text

Abstract:

Background: Bronchial Asthma is one of the worldwide health problems associated with increased morbidity and also mortality. Bronchial Asthma is a disease of airways that is characterized by increased responsiveness of the trachea-bronchial tree. Anti asthmatic drugs are associated with adverse effects which can affect the compliance and course of treatment. Monitoring adverse drug reactions in asthma will play a vital role in alerting physicians about the possibility and circumstances of such events, thereby protecting the user population from avoidable harm.Methods: The study was conducted in 500 bronchial asthma patients (250 patients in Beta 2 agonist group (Salbutamol) and 250 patients in Methylxanthine group (Deriphyllin) who fulfilled the study criteria and were observed for three months at Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai. Their prescriptions were collected and analysed. Adverse drug reactions(ADRs) in each group were collected and evaluated. The causality assessment was done by WHO-UMC assessment scale and severity by using Modified Hartwig-Seigel severity assessment scale.Results: Total 38% of patients taking anti-asthma drugs were encountered adverse drug reactions and were more common in elderly females (61 to 70 years). Adverse Drug Reactions were more common in Methylxanthine group (48%) compared to Beta 2 agonist group (28%). Headache (38%) was the commonest ADR in Methylxanthine group and Tremors (31%) in Beta 2 agonist group. Most of ADRs were mild (95 %), manageable and comes under possible (60 %) category of WHO causality assessment scale.Conclusions: Treatment of Bronchial Asthma is mainly based on Beta 2 agonist and Methylxanthine group. So, occurrence of ADR is much common. Our study offers a representative idea of the ADR profile of anti asthmatic drugs. Constant vigil in detecting ADRs and subsequent dose adjustments can make therapy with anti asthmatic drugs safer and more effective. This, in turn, will improve compliance.

APA, Harvard, Vancouver, ISO, and other styles

9

Du, Chunhua, Qi Zhang, Lina Wang, Mei Wang, Jinfeng Li, and Qian Zhao. "Effect of Montelukast Sodium and Graphene Oxide Nanomaterials on Mouse Asthma Model." Journal of Nanoscience and Nanotechnology 21, no. 2 (February 1, 2021): 1161–68. http://dx.doi.org/10.1166/jnn.2021.18705.

Full text

Abstract:

Because some asthma patients have different types of inflammatory cells in their bodies, they cannot get relief with traditional drugs. However, the nano drug delivery system can realize efficient drug delivery, inflammatory cells and intracellular targeting, and the apoptosis of inflammatory cells. This article aims to comprehensively evaluate the effects of montelukast sodium combined with graphene oxide nanomaterials on improving the clinical symptoms and airway inflammation of children with bronchial asthma, with a view to further improving the clinical treatment of children with bronchial asthma. The results show that montelukast sodium can improve lung function in patients with asthma, and also has important effects such as anti-inflammatory and regulating immune function. After exposure to graphene oxide, the level of oxidative stress in mice increased with brightness and humidity, demonstrating the role of T oxidative stress in the development of asthma. In addition, nanocarriers assist co-loaded drugs to deepen and enrich the pulmonary inflammation site, further achieving effective mitochondrial targeted drug delivery, thereby enhancing the inhibitory effect of anti-apoptotic proteins, leading to inflammatory cell apoptosis.

APA, Harvard, Vancouver, ISO, and other styles

10

HOLDCROFT, CAROL. "Nedocromil: A New Anti-inflammatory Drug for Asthma." Nurse Practitioner 19, no. 3 (March 1994): 7–8. http://dx.doi.org/10.1097/00006205-199403000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Anti asthma drug"

1

Unali, Giovanni Francesco. "Synthesis and characterisation of methacrylate-based water-soluble diblock and triblock copolymers for drug dispersion in aqueous media." Thesis, University of Sussex, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.341075.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lamming, E. D. "Synthesis of N-heterocycles as anti-asthma drugs and compounds with antimycobacterial properties." Thesis, University College London (University of London), 2015. http://discovery.ucl.ac.uk/1473279/.

Full text

Abstract:

Part A: Synthesis of N-heterocycles with dual pharmacology for the treatment of asthma The most common and effective anti-inflammatory asthma treatment is carried out through use of steroids but these can have significant side effects. An alternative non-steroidal oral treatment is montelukast which targets the leukotriene inflammatory pathway, but is less effective at controlling asthma symptoms. The asthma inflammation pathway is complex involving many inflammatory mediators, and it was anticipated that a compound with dual pharmacology which impacted both leukotriene and prostaglandin pathways simultaneously would yield compounds with an enhanced ability to treat asthma. An attractive novel dual target strategy was the inhibition of the 5-lipoxygenase activating protein (FLAP) and antagonism of the prostaglandin D2 receptor CRTh2. A combination of GlaxoSmithKline and literature SAR studies were elaborated in the design of the target compounds, incorporating known pharmacophores for FLAP inhibitors and CRTh2 antagonists. Synthetic routes towards the target compounds were developed and their biological activity against the intended targets determined. Part B: Synthesis of tetrahydroisoquinolines, tetrahydrobenzazepines and profens and their antimycobacterial properties Tuberculosis (TB) is an infectious disease caused by the Mycobacterium tuberculosis pathogen. The increasing prevalence of drug resistant strains of M. tuberculosis means there is an urgent need to develop new anti-TB drugs with novel modes of action. Aporphine alkaloid natural products and synthetic tetrahydroisoquinolines have demonstrated a specific antimycobacterial effect, as well as M. tuberculosis MurE inhibitory activity. The tetrahydroisoquinoline skeleton therefore provides a unique template for the development of new anti-TB drugs. Recently we developed biomimetic reaction conditions for the Pictet-Spengler condensation of aldehydes and amines into tetrahydroisoquinolines. The reaction is mediated by phosphate and proceeds under mild reaction conditions. The scope of the phosphate mediated Pictet-Spengler reaction was investigated in order to access novel alkaloid structures and identify new leads for mycobacterial growth inhibitors. Studies into asymmetric versions of the reaction using chiral phosphates and extending the reaction for the construction of larger ring sizes were explored. Another interesting class of compounds recently identified as active against mycobacterial growth were non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. Analogues of profen compounds were synthesised for evaluation as mycobacterial growth inhibitors.

APA, Harvard, Vancouver, ISO, and other styles

3

Morales, Daniel. "Quantifying the risk of beta-blockers and non-steroidal anti-inflammatory drugs in asthma." Thesis, University of Dundee, 2014. https://discovery.dundee.ac.uk/en/studentTheses/56ca8828-73f6-47cc-b919-6e3e78e11a7b.

Full text

Abstract:

Beta-blockers and non-steroidal anti-inflammatory drugs (NSAIDs) are often avoided in asthma over risk of bronchospasm which may vary according to drug selectivity and duration of administration. This thesis attempts to quantify the risk of beta-blocker and NSAID exposure in asthma by synthesising clinical trial evidence and conducting observational studies using linked electronic medical records. As part of this thesis, three systematic reviews of clinical trials were conducted evaluating: the prevalence of aspirin-exacerbated respiratory disease (AERD); risk of selective NSAIDs/COX-2 inhibitors in people with AERD; and risk of acute beta-blocker exposure in people with asthma. Electronic primary care data from the Clinical Practice Research Datalink (CPRD) was used to define a cohort of people with active asthma, measure the prevalence of beta-blocker and NSAID prescribing, and perform a series of nested case control studies evaluating asthma death, asthma hospitalisation and primary care asthma exacerbations (PCAE). A self-controlled case-series was performed for PCAE as well. Based upon work in this thesis, the prevalence of AERD in people with asthma was around 9%. Selective NSAIDs triggered respiratory symptoms in 8% of people with AERD whilst no significant changes in lung function or symptoms occurred with COX-2 inhibitors. Acute non-selective beta-blocker exposure caused a significant mean fall in FEV1 of 10%, a significant increase in respiratory symptoms in around 1 in 13 and a non-significant increase in falls in FEV1 of ≥20% in around 1 in 9. Acute selective beta-blocker exposure caused a significant mean fall in FEV1 of 7%, significant falls in FEV1 of ≥20% in around 1 in 8 and a non-significant increase in respiratory symptoms in around 1 in 33. The prevalence of selective beta-blocker prescribing in asthma rose by around 200% over the 12 year period whilst the prevalence of non-selective beta-blocker prescribing rose by around 90%. Changing trends in NSAID prescribing occurred over the 12 year period with COX-2 inhibitors now rarely prescribed. Using the nested case control design, both incident and high-dose non-selective beta-blocker exposure was associated with significantly increased risk of asthma morbidity (hospitalisation and PCAE). In contrast, no significant increased risk of asthma morbidity occurred with any type of selective beta-blocker exposure. Consistent findings were seen for PCAE using the self-controlled case series. No significantly increased risk was seen with different oral NSAIDs apart from weak evidence of an association between asthma death and non-selective NSAID exposure which is unlikely to be causal. Significant numbers of people with asthma are prescribed beta-blockers and NSAIDs. Evidence from clinical trials and observational studies demonstrate that non-selective beta-blockers significantly increase asthma morbidity with risk appearing to vary according to dose and duration of administration. Although selective beta-blockers have the potential to cause significant changes in lung function, no significant increase in asthma morbidity was observed in observational studies. Although around 9% of asthmatics may be susceptible to NSAIDs, no strong evidence was found to suggest that the current practice of NSAID prescribing increases asthma morbidity. At the same time, COX-2 inhibitors are infrequently prescribed despite apparently being well tolerated by people with AERD.

APA, Harvard, Vancouver, ISO, and other styles

4

蘇晏群. "Design and Synthesis of Novel Anti-asthma Drug." Thesis, 2019. http://ndltd.ncl.edu.tw/handle/gxqxt3.

Full text

Abstract:

碩士
國立彰化師範大學
化學系
107
Asthma is a common chronic bronchial inflammatory disease and is characterized by airway obstruction, airway inflammatory, and airway hyperresponsiveness. Since the 1970s, asthma has spread widely throughout the world. By 2015, 300 million to 400 million people worldwide have been affected. The death toll also came to around 400,000 people. Asthma results from complex interactions among inflammatory cells, mediators, and the cells and tissues resident in the airways. The exact cause is not fully understood, so the current asthma can not be cured, and drugs can only be used to achieve effective control of the disease. However, the current air quality is getting worse and worse, the problem of PM 2.5 is getting worse, and the rate of asthma attacks has increased by 40%. We want to develop effective new anti-asthma drugs, so we combined the anti-asthma drug Theophylline with Ozagrel to anticipate the combination of these two drugs for different modes of action in asthma. They can complement each other so that the drug can achieve the same or better therapeutic effect in a low dose. For patients who cannot tolerate high doses, the low dose mode can reduce the side effects of the patient on high doses of the drug.

APA, Harvard, Vancouver, ISO, and other styles

5

Wu, Li-Ping, and 吳麗評. "Biosensor for detection of asthma biomarker-ECP and anti-cancer drug-cisplatin." Thesis, 2014. http://ndltd.ncl.edu.tw/handle/99m4wp.

Full text

Abstract:

碩士
國立交通大學
應用化學系碩博士班
102
Eosinophil cationic protein (ECP) was used as biomarker for asthma, which was been proved that bound with heparin and heparan sulfate existeded on cell membrane specifically. Based on the specific binding between ECP and heparin and heparan sulfate, gold nanostructured platform was simply formed on the working electrode through controlled electrodeposition, and then, the heparin was immobilized on the gold nanoparticles using the cysteamine as the linker. A electrochemical biosensor for detection of asthma biomarker was developed. other research of our lab improved the detection of ECP by immobilizing heparin on the Au@Fe3O4 NPs. This study further investigated the functional magnetic nanoparticles (Hep-Au@Fe3O4 NPs) in biological applications. We confirmed the functional magnetic nanoparticles are non-toxic and have potential to target drug development. The functional magnetic nanoparticles could be further applied into more extensively usages in the future. Cisplatin is commonly used in chemotherapy. But the side-effects it caused often makes patients discomfortable and even affects their liver and kidney function. Some studies have indicate that the binding between cisplatin and guanine will interfere the formation of DNA double-stranded structure. In this study, we used the telomere of human, a region of repetitive nucleotide sequences that contained a lot of quanine , combining with the character that performing larger fluorescence signal after binding to double-stranded DNA of SYBR ® Green.A simple strategy to sensitively detect cisplatin in human serum have developed. This method may have good prospects for drug research and development field.

APA, Harvard, Vancouver, ISO, and other styles

6

Ho, I.-Jen, and 何逸人. "The Anti-asthma Drugs used in Taiwan." Thesis, 2007. http://ndltd.ncl.edu.tw/handle/75775493625154231863.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Anti asthma drug"

1

Holgate, S. T., and Riccardo Polosa. Asthma: Current treatments. Oxford: Clinical Pub., 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Sampson, Anthony P., and Martin K. Church, eds. Anti-Inflammatory Drugs in Asthma. Basel: Birkhäuser Basel, 1999. http://dx.doi.org/10.1007/978-3-0348-8751-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

O’Donnell, Stella R., and Carl G. A. Persson, eds. Directions for New Anti-Asthma Drugs. Basel: Birkhäuser Basel, 1988. http://dx.doi.org/10.1007/978-3-0348-9156-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

R, O'Donnell Stella, Persson C. G. A, and International Congress of Pharmacology, (10th : 1987 : Sydney, N.S.W.), eds. Directions for anti-asthma drugs. Boston: Birkhauser, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

1962-, Sampson Anthony P., and Church Martin 1942-, eds. Anti-inflammatory drugs in asthma. Basel: Birkhäuser, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Directions for new anti-asthma drugs. Basel: Birkhauser, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

(Editor), Anthony P. Sampson, and Martin Church (Editor), eds. Anti-Inflammatory Drugs in Asthma (Pir (Series).). Birkhauser, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

(Editor), Riccardo Polosa, and Stephen T. Holgate (Editor), eds. Therapeutic Strategies in Asthma: Current Treatments. Clinical Publishing, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Barnes, Peter. Asthma Therapy. Taylor & Francis, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

(Editor), K. E. Andersson, and C.G.A. Persson (Editor), eds. Anti-asthma Xanthines and Adenosine (Current clinical practice series). Elsevier, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Anti asthma drug"

1

Cuss, Francis M. "Is Choice of Drug Delivery as Important as Choice of Drug in Childhood Asthma?" In Directions for New Anti-Asthma Drugs, 277–83. Basel: Birkhäuser Basel, 1988. http://dx.doi.org/10.1007/978-3-0348-9156-1_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

O’Donnell, Stella R. "Airway Microvascular Permeability in Asthma: A Target for Drug Action?" In Directions for New Anti-Asthma Drugs, 217–38. Basel: Birkhäuser Basel, 1988. http://dx.doi.org/10.1007/978-3-0348-9156-1_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Barnes, Peter J. "The Drug Therapy Of Asthma: Directions For The 21St Century." In Directions for New Anti-Asthma Drugs, 293–313. Basel: Birkhäuser Basel, 1988. http://dx.doi.org/10.1007/978-3-0348-9156-1_23.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Paterson, James W., Karmelo M. Lulich, and Roy G. Goldie. "An Overview of the Current Status of the Drug Therapy of Asthma." In Directions for New Anti-Asthma Drugs, 15–33. Basel: Birkhäuser Basel, 1988. http://dx.doi.org/10.1007/978-3-0348-9156-1_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Svensson, Leif-Å. "Bambuterol, A Bronchodilator Prodrug with Sustained Action, Enhances Delivery of Active Drug to the Lung." In Directions for New Anti-Asthma Drugs, 271–76. Basel: Birkhäuser Basel, 1988. http://dx.doi.org/10.1007/978-3-0348-9156-1_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Prentice, Bernadette, Adam Jaffe, and Paul S. Thomas. "Anti-asthma Drugs, Overview." In Encyclopedia of Inflammatory Diseases, 1–6. Basel: Springer Basel, 2014. http://dx.doi.org/10.1007/978-3-0348-0620-6_6-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Prentice, Bernadette, Adam Jaffe, and Paul S. Thomas. "Anti-asthma Drugs, Overview." In Compendium of Inflammatory Diseases, 64–69. Basel: Springer Basel, 2016. http://dx.doi.org/10.1007/978-3-7643-8550-7_6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Tenor, Hermann, and Christian Schudt. "Phosphodiesterases in Asthma." In Anti-Inflammatory Drugs in Asthma, 87–135. Basel: Birkhäuser Basel, 1999. http://dx.doi.org/10.1007/978-3-0348-8751-9_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Lordan, James L., and Ratko Djukanović. "Anti-Inflammatory Drugs in Asthma: The Pathophysiology of Asthma." In Anti-Inflammatory Drugs in Asthma, 1–33. Basel: Birkhäuser Basel, 1999. http://dx.doi.org/10.1007/978-3-0348-8751-9_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

O’Donnell, Stella R., and Carl G. A. Persson. "New Drugs for Asthma." In Directions for New Anti-Asthma Drugs, 317–25. Basel: Birkhäuser Basel, 1988. http://dx.doi.org/10.1007/978-3-0348-9156-1_24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Anti asthma drug"

1

Cheong, D. H. J., A. S. L. Phua, I. R. J. Tan, Y. Qiao, J. Dong, F. W. S. Wong, and T. Tran. "Anti-Remodelling and Anti-Airway Hyperresponsiveness Properties of Anti-Malarial Drug, Artesunate, in a House Dust Mites-Induced Chronic Mouse Model of Asthma." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2842.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Brown, Mary, Rainard Fuhr, Hong-Lin Su, Yingxue Chen, Henrik Forsman, Helen Jackson, and Ajay Aggarwal. "A randomized trial of AZD7594 a novel non-steroidal anti-inflammatory drug in asthma patients." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.oa277.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Efthymiopoulos, Konstantinos, Jill Reckless, Catherine Overed-Sayer, Val Piercy, Ian Purvis, David Fox, Dan Wheeler, and David Grainger. "The Type 2 Somatostatin Receptor, The Putative Target For The Novel Anti-Inflammatory Drug FX125L, Is Expressed At Normal Levels By Both Sputum And Peripheral Blood Leukocytes From Patients With Mild-To-Moderate Asthma." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a4460.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Fortin, Marylène, Kamel Moktefi, Mary Jane Court, Serge Séguin, and Nicolay Ferrari. "TPI ASM8, An Inhaled Antisense Oligonucleotide Drug Candidate Targeting CCR3 And The Common Beta Chain Of IL-3, IL-5 And GM-CSF Receptors, Potentiates The Anti-inflammatory Activity Of An Inhaled Corticosteroid In A Rat Model Of Asthma." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5694.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Van Ganse, Eric H., Laurent Laforest, Idlir Licaj, Gilles Devouassoux, Gerard Chatte, and Jennifer Martin. "Medical Resource Utilization In Asthma Patients Under Inhaled Corticosteroids (ICS) With Higher Ratios "Inhaled Corticosteroids-To-Total Anti-Asthma Drugs": French Claims Data." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a5223.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Van Ganse, Eric H., Laurent Laforest, Idlir Licaj, Gilles Devouassoux, and Gerard Chatte. "Individual Ratios "Inhaled Corticosteroids-To-Total Anti-Asthma Drugs" In Primary Care Electronic Medical Records: Results And Methodological Implications." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a3245.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Balasaniantc, Goar, Zhanna Rakisheva, Anna Zepke, Akmaral Akisheva, and Nataliya Solovjeva. "Spreading of resistance to group A anti-tuberculosis drugs among TB patients in Astana city." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa4744.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ikeda, Katsuhito, John P. Bell, Masamitsu Aoki, Tatsuo Nakayama, Kazuo Eiho, Masako Onishi, Haruo Takaku, and Fumio Nishikaku. "AZD8848/DSP-3025, A Novel TLR7 Agonist Ante-Drug, Demonstrates Efficacy Against Airway Obstruction And Other Inflammatory Endpoints In Guinea Pig Models Of Rhinitis And Asthma With Acute And Weekly Dosing." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4242.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!